GPR35 Agonist
Inflammatory Bowel Disease (IBD)
PreclinicalActive
Key Facts
About Nxera Pharma
Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease (IBD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DFTX-201 | Definium Therapeutics | Preclinical |
| COSMO-232 | Cosmo Pharmaceuticals | Preclinical |
| Tamuzimod | Ventyx Biosciences | Phase 2 |
| VTX958 | Ventyx Biosciences | Phase 2 |
| SL-325 | Shattuck Labs | Phase 2 |
| SL-425 | Shattuck Labs | Phase 1 |
| ABS-101 | AbSci | Pre-clinical |
| Metabolite Delivery Platform (Therapeutic Programs) | ClostraBio | Pre-clinical |
| ABO21009 | AboleIIs Pharma | Phase 1 |